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Abstract 
Background: Chronic insomnia is a common medical condition that negatively impacts quality of life and daytime function. Access to 
the first-line treatment for insomnia, cognitive behavioural therapy (CBT-i), is limited. Pharmacists are well positioned to provide this 
service, but evidence regarding pharmacist delivered CBT-i is sparse. The aim of this study was to evaluate the effectiveness of CBT-i 
delivered by pharmacists practicing in an outpatient clinic setting. 
Methods: This study was a retrospective chart audit of adult patients with chronic insomnia who received CBT-i from a pharmacist at 
one of two outpatient clinics in Canada. The primary endpoints were the differences between patient self-reported sleep diary 
parameters and utilization of hypnotic medications before and after CBT-i was delivered. The differences in patient reported sleep 
parameters were compared using Wilcoxon Signed Rank test and paired samples t-test and changes in hypnotic utilization was 
compared using McNemar Chi-square test. 
Results: 183 patients were referred for CBT-i and attended an initial appointment with a pharmacist. Of these, 105 did not receive the 
CBT-i. This resulted in 78 patients who met the inclusion criteria. Changes in sleep diary parameters were all  statistically significantly 
improved after patients received CBT-i, except for total sleep time. Hypnotic medication use was also reduced. At baseline, 71.8% 
(n=56/78) of patients were taking one or more hypnotic medications compared to 52.6% (n=41/78) after CBT-i (p=0.0003).  
Discussion: The results of this study provide preliminary evidence that pharmacists working in an outpatient clinic setting may be able 
to effectively deliver CBT-i for patients with chronic insomnia. The external validity of these results is limited by the observational study 
design and the inclusion of pharmacists practicing in outpatient clinics, which is not the setting where most pharmacists currently 
practice.  
Conclusion: This observational study found improvements in sleep quality and efficiency, as well as, a reduction in hypnotic medication 
use, in patients who received CBT-i from pharmacists practicing in an outpatient clinic setting. Future randomized, controlled trials 
should evaluate the impact of CBT-i in a larger sample of patients, provided by pharmacists practicing in both outpatient clinics and 
community pharmacies. 
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Introduction 
Chronic insomnia is defined as the frequent inability to initiate 
and/or maintain sleep, experiencing non-restorative sleep, 
and/or early morning awakenings lasting greater than three 
months.1–3 Chronic insomnia can also cause a number of 
daytime symptoms such as fatigue, sleepiness, poor 
concentration, and irritability.1 Chronic insomnia can even 
impact the physical and mental health of individuals by 
increasing the risk of cardiovascular disease, diabetes, obesity, 
and depression.2 This condition also negatively impacts society 
through decreased productivity and increased absenteeism 
from school and work.4  
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Several professional organizations, including the American 
Academy of Sleep Medicine, the American College of 
Physicians, Toward Optimized Practice (Canada) and the 
European Sleep Research Society, recommend Cognitive 
Behavioural Therapy (CBT-i) as the first-line treatment for 
chronic insomnia.5–9 However, in many cases, patients seeking 
help for this condition are initiated on a hypnotic medication 
during their initial encounter with a healthcare professional.1,10 
For instance, a study in Australia found that community 
pharmacists recommended an over-the-counter sleep aid as 
first-line therapy in 96% of sleep complaint cases.11  
 
The evidence for use of hypnotic medications, such as 
benzodiazepines and z-drugs (i.e., zopiclone, zolpidem), is 
limited to short-term treatment (i.e., less than four weeks) and 
these medications are not indicated for chronic use.7,12 Patients 
can also develop physiological and psychological dependence 
to hypnotic medications if they are used on a continuous basis.1 
Additionally, hypnotic medications have high rates of adverse 
Original Research PHARMACY PRACTICE 
 
http://z.umn.edu/INNOVATIONS                          2020, Vol. 11, No. 3, Article 2                     INNOVATIONS in pharmacy 
                                                                             DOI: https://doi.org/10.24926/iip.v11i3.3378 
2 
 
effects including drowsiness and fatigue, which can result in 
falls and motor vehicle accidents.13,14 The risks of hypnotics, 
along with their limited long term effectiveness, justify the 
importance of focusing on CBT-i as the first-line treatment for 
chronic insomnia.  
 
The provision of CBT-i includes offering patients an 
individualized combination of cognitive, behavioural, and 
educational interventions to treat the chronic insomnia. CBT-i 
consists of six components that are typically completed over an 
average of 4-10 sessions with a trained health professional. 
These components include stimulus control, sleep restriction, 
sleep hygiene, cognitive restructuring, relaxation training, and 
other stress reduction techniques.15 The efficacy of CBT-i has 
been demonstrated in many clinical trials and systematic 
reviews and includes significant improvements in both sleep 
quality and quantity.16–22 Despite the negative impact that 
comorbid medical and psychiatric conditions can have on sleep 
disorders, CBT-i has been shown to be efficacious in patients 
with stable depression or anxiety, post-traumatic stress 
disorder, substance use disorder, and chronic pain.23–26 A study 
by Jacobs et al. concluded that CBT-i was more efficacious than 
pharmacotherapy alone and that pharmacotherapy in addition 
to CBT-i provided no added long term benefit.27 Unlike hypnotic 
medications, which have evidence for only short-term 
effectiveness, improvements in sleep have been shown to be 
sustained for up to 24 months after CBT-i has been 
completed.28 
 
The primary limitation of CBT-i, when delivered in-person by a 
health care provider, is that it is a service that requires 
significant time, specialized training, and numerous follow-up 
patient interactions.29 Consequently, there is a limited number 
of health professionals who provide CBT-i, despite the evidence 
for its effectiveness.30 Previous studies have found that CBT-i 
can be effectively delivered by non-sleep specialists, such as 
nurses, psychologists, therapists, and social workers.18,25,31,32 
Unfortunately, patient access to this service remains limited 
and the need to train more primary health workers to provide 
CBT-i has been discussed widely in the literature.29,33,34  
 
Pharmacists are well positioned to provide CBT-i due to their 
highly accessible position in the health systems of many 
countries. Historically, pharmacists have been commonly 
involved in providing education and follow-up care related to 
the use of hypnotics. 35,36 A review by the Canadian Agency for 
Drugs and Technologies in Health (CADTH) reported that 62% 
of surveyed pharmacists discuss behavioural interventions (e.g. 
sleep hygiene, relaxation training, stimulus control) during their 
prescription counselling sessions with patients starting 
treatment with hypnotics.10 However, there is very limited 
published research on pharmacists providing CBT-i. One small 
observational study reported data from 11 patients in Canada 
who had improvements in some sleep parameters after 
receiving CBT-i from pharmacists.37 A slightly larger study by 
Fuller et al. (n=41) measured the impact of pharmacist-
provided behavioural interventions for insomnia patients; 
however, the intervention was comprised of only two of the six 
components of CBT-i (i.e., stimulus control and sleep 
restriction).38 The aim of this study was to evaluate the 
effectiveness of CBT-i delivered by pharmacists practicing 
within an outpatient clinic setting in Canada. The primary 
endpoints were the differences between patient self-reported 
sleep diary parameters and utilization of any hypnotic 
medication before and after the CBT-i service was delivered.  
 
METHODS 
This study was a retrospective chart audit of adult patients (>18 
years) who received CBT-i from a pharmacist at one of two 
outpatient clinics in Saskatoon, Saskatchewan (Canada), the 
Medication Assessment Centre (MAC) and West Winds Primary 
Health Centre (WWPHC). Both clinics have a pharmacist on staff 
who offers individual patient consultations, in an office-based 
setting, on referral from a health professional or from patients 
directly. These clinics do not include a dispensary and the 
pharmacists do not fill prescriptions.  
 
Pharmacists at the MAC and WWPHC received training to 
provide CBT-i by attending a professional development 
program called PharmaZzz, which was offered by the College of 
Pharmacy and Nutrition at the University of Saskatchewan. 
Pharmacists enrolled in the PharmaZzz program were provided 
with a self-study manual, which explained how to provide CBT-
i and included a stepwise approach to providing the service. 
Participants were also provided with a supply of workbooks 
that could be given to patients during CBT-i consultations, 
which provided detailed insomnia patient education and a 
sleep diary. The self-study manual and patient workbook were 
developed from existing models for CBT-i and adapted for 
pharmacy practice by psychiatry faculty at the University of 
Saskatchewan. After completing the self-study manual, 
pharmacists were required to attend a one day in person 
workshop in which local physician and pharmacist sleep experts 
provided additional educational content on the 
pathophysiology of sleep disorders, CBT-i theory and 
application, patient assessment, tapering of hypnotics, and 
interpretation of sleep logs. Participants in the one-day 
workshop also had the opportunity to role play and receive 
feedback from workshop facilitators to complete the CBT-i 
training program.       
 
Chronic insomnia is commonly clinically assessed using patient 
self-reported sleep diary parameters, which are typically 
collected during CBT-i consultations.3 These parameters 
include: the time it takes for an individual to fall asleep (known 
as sleep onset latency or SOL); the sum of awake time occurring 
between initial sleep onset and the final morning awakening 
(known as wake after sleep onset ,lkor WASO); the total 
number of hours of sleep (known as total sleep time or TST); 
and the proportion of time spent in bed actually asleep (known 
as sleep efficiency or SE).4 The severity of chronic insomnia, 
from the patient’s perspective, can also be assessed using the 
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validated Insomnia Severity Index (ISI) questionnaire, which 
includes a variety of patient-reported sleep measures.5 
Guidelines suggest that the goals for chronic insomnia 
management are to improve sleep quality and duration by 
reducing both SOL and WASO to less than 30 minutes and 
increasing SE to greater than 80-85%.5 The primary endpoints 
of this study were the differences between all of these patient 
self-reported sleep diary parameters and utilization of hypnotic 
medications before and after the CBT-i service was delivered by 
the two pharmacists at WWPHC and the MAC.  
 
All patients, 18 years and older, who received CBT-i from a 
pharmacist at either the MAC or WWPHC between August 2016 
and June 2019 were included in this study. Patients were 
excluded if they had an inadequately controlled medical 
condition that would make them a poor candidate for CBT-i 
(e.g., generalized anxiety disorder). Chart data of patients who 
met the inclusion criteria were extracted from the electronic 
medical records (EMR) at the MAC and WWPHC in July 2019. 
Data extraction was performed by an undergraduate research 
student at the University of Saskatchewan who was not part of 
the clinical team at either WWPHC or the MAC. The following 
patient self-reported sleep diary parameters were collected, 
both pre and post implementation of the CBT-i service, (if they 
were documented by the pharmacist in the EMR): SOL, WASO, 
the total number of nighttime awakenings, total time in bed 
(TIB), TST, SE (calculated by dividing the TST by the TIB), and the 
ISI score. Pre-implementation parameters were defined as 
those collected by the pharmacist at the initial consultation, 
before any cognitive or behavioral interventions were 
implemented. Post-implementation parameters were defined 
as those collected by the pharmacist at the most recent 
consultation, after all planned cognitive and behavioral 
interventions were implemented. 
 
Hypnotic medication utilization was measured by comparing 
the baseline patient medication lists in the EMR, compiled by 
the pharmacist at the initial CBT-i appointment, with the 
medication lists compiled at the final follow-up CBT-i 
appointment. Any medication that the patient reported to be 
taking for sleep was included, even if the medication was not 
officially indicated for the treatment of insomnia. This includes 
prescription/non-prescription medications, natural products, 
or supplements. If there were any differences between the 
medication lists (e.g. hypnotic medication additions, 
discontinuations, or dose changes) the charts were reviewed to 
determine if the changes were directly related to a 
recommendation made by the pharmacist (i.e., if there was a 
documented recommendation made by the pharmacist in the 
EMR). Only changes to hypnotic medication utilization that 
were specifically recommended by the pharmacists were 
included in the analysis.  
 
The differences in patient reported SOL, WASO, total number 
of nighttime awakenings, total TIB, SE, and ISI scores pre and 
post CBT-i were compared using the Wilcoxon Signed Rank test. 
Changes in TST were compared using the paired samples t-test 
and changes in hypnotic utilization were compared using the 
McNemar Chi-square test. Data analyses were completed using 
IBM SPSS Statistics software (Version 25.0. Armonk, NY: IBM 
Corp). This research protocol was approved by the University of 
Saskatchewan research ethics board.   
 
RESULTS 
A total of 183 patients were referred for CBT-i and attended an 
initial appointment with a pharmacist at either the MAC or 
WWPHC. However, 105 of these patients did not receive the 
CBT-i service for one or more of the following reasons: 
pharmacist decided the patient was not a good candidate for 
CBT-i (n=19/105, 18.1%), the patient refused the CBT-i 
intervention after learning what it entailed (n=32/105, 30.5%), 
and the patient did not return for follow-up for unknown 
reasons (n=54/105, 51.4%). This resulted in 78 patients who 
received the CBT-i intervention, met the inclusion criteria, and 
were included in the analyses (Figure 1). The majority of 
patients included in this study (71.8%) were taking one or more 
hypnotic medication at baseline and the most commonly used 
hypnotics were zopiclone (53.6%), trazodone (12.5%), and 
melatonin (10.7%) – Table 1.  
 
The mean number of documented, pharmacist-delivered,  
CBT-i appointments was 5.1 per patient (range of 3-13). The 
patient self-reported sleep diary parameters, along with the ISI 
scores, were all statistically significantly improved after 
patients received CBT-i, except for the TST (Table 2). Hypnotic 
medication use was also statistically significantly reduced after 
patients completed CBT-i. At baseline, 71.8% (n=56/78) of 
patients were taking one or more hypnotic medication 
compared with 52.6% (n=41/78) after CBT-i (p=0.0003). Of the 
41 patients who remained on one or more hypnotic medication 
after receiving CBT-i, 66.1% (n=27/41) were taking a reduced 
dose.     
 
Discussion 
Previous research has consistently found that CBT-i can be 
effectively delivered by a broad range of non-sleep specialist 
health care professionals, such as nurses, psychologists, 
therapists, and social workers.18,25,31,32 The results of this non-
randomized, observational study add unique and valuable data 
to the existing literature by providing preliminary evidence that 
pharmacists working in an outpatient clinic setting may also be 
able to effectively deliver CBT-i for patients with chronic 
insomnia.  
 
The improvements in sleep parameters observed in this study 
are similar to those reported in previous studies in which other 
non-sleep specialist health professionals performed the  
CBT-i.18,25,31,32  This offers some confidence in the validity of 
these results since the CBT-i provided by the pharmacists in this 
study had a similar effect as was reported in previous research 
not involving pharmacists. Similarly, the range of patient 
appointments that was required for the pharmacists to deliver 
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the service in this study (i.e., 3-13 appointments) was similar to 
findings in previous research of other health professionals who 
provided CBT-i (i.e., 4-10 appointments).18,25,31,32   
 
The improvements in sleep quality and efficiency reported in 
this study also appear to be clinically meaningful. Sleep onset 
latency (SOL) was reduced to less than 30 minutes and SE 
improved to over 85%, which are both considered successful 
treatment targets defined in insomnia guidelines.5 It may be 
more useful to interpret these data by simply considering the 
raw numbers. At baseline, on average, patients were taking 
approximately 48 minutes to fall asleep and were awake for 
over 60 minutes during the night. After CBT-i, both of these 
parameters were reduced by almost 50%, which is an 
improvement that patients would likely find to be meaningful 
(Table 2). It is not surprising that total sleep time was 
unchanged in this study, as previous research has reported a 
similar finding.18,25,31,32 Individuals diagnosed with chronic 
insomnia typically have difficulty falling asleep and/or do not 
sleep efficiently (i.e., wake up frequently, do not have 
restorative sleep), despite often getting the recommended or 
close to recommended total quantity of sleep throughout an 
entire day.  
 
The improvements observed in the ISI scores provide additional 
evidence of the clinical importance of the results of this study. 
The previously validated ISI is frequently used in research, and 
in clinical practice, to assess and quantify response to 
treatment.39 The minimal clinically important difference for the 
ISI score is considered to be a change of at least 7 points and a 
change greater than 9 points is considered to be a “marked 
improvement”.39 The results of this study found that mean ISI 
scores improved by 10.3 points, from a baseline of 18.2 
(defined as ‘moderately severe insomnia’) to 7.9 (defined as 
‘subthreshold insomnia’), suggesting that, on average, patients 
in this study had a marked improvement in their chronic 
insomnia symptoms.  
 
This study also found a statistically significant reduction in 
overall hypnotic medication use. It was not a pre-defined study 
endpoint to perform separate statistical analyses on changes 
related to each different hypnotic agent; however, zopiclone 
was, by far, the most commonly utilized medication in this 
study. This is an important finding as this suggests that the 
patients were sleeping better despite taking fewer medications 
after CBT-i. Hypnotic usage was reduced from 71.8% to 52.6% 
of patients, an absolute reduction of 19.2%. In addition, almost 
two-thirds of patients, who remained on a hypnotic after CBT-i 
was completed, were taking a lower dose.  
 
It is important to note the large proportion of patients who 
were referred for CBT-i, attended an initial appointment, but 
did not actually receive the service (n=105/183, 57.3%). This 
finding is not surprising, as many patients may not be suitable 
candidates for CBT-i (e.g., poorly controlled psychiatric co-
morbidities, secondary insomnia, contraindication for CBT-i) 
and often this may not be identified until after the initial CBT-i 
appointment. Additionally, the cognitive and behavioural 
interventions required of patients undergoing CBT-i are 
challenging and require significant patient motivation, 
determination, and commitment, thus, it is understandable 
that many patients may decline CBT-i after they learn about 
what it entails during the initial appointment, as was observed 
in this study. 
 
There are some significant limitations to this study that suggest 
the results should be applied into practice with caution and 
interpreted as hypothesis generating. Most importantly is the 
non-randomized, uncontrolled, observational study design, 
which was selected intentionally to determine if there was an 
initial signal that there may be some value to pharmacist-led 
CBT-i. One of the primary endpoints, changes in sleep diary 
parameters, relies completely on patient self-reporting of data. 
Although these endpoints are commonly used in research 
related to chronic insomnia, there is no way to verify the 
accuracy or reliability of the patient’s sleep diaries. In addition, 
this study evaluated a service provided by only two pharmacists 
who both practice in a non-dispensing, outpatient, primary care 
clinic setting. It is not known if these results would be similar if 
provided by a large sample of pharmacists in a community 
pharmacy setting. Finally, this study did not collect data on 
long-term consequences of chronic insomnia (i.e., 
performance/attendance at work/school) and only reported 
changes in patient self-reported sleep parameters and hypnotic 
medication usage.  
 
Conclusions 
Pharmacist-led CBT-i, performed within two non-dispensing, 
outpatient clinics in Canada, resulted in statistically significant 
and clinically meaningful improvements in sleep quality and 
efficiency, along with reductions in hypnotic medication 
utilization. This is important new information that provides a 
strong rationale for larger scale studies to be completed to 
further evaluate the role of pharmacists providing CBT-i. 
Additional randomized, controlled studies should be performed 
to confirm these results in a much larger sample of patients, 
recruited from multiple locations, and including pharmacists 
practicing in both outpatient clinic and community pharmacy 
settings.   
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Table 1: Baseline Participant Demographics (n=78) 
 
Female gender - # (%)  64 (82.1) 
Mean age – yr  54.9 
Mean total medication count   5.8 
Hypnotic use (any) – # (%)  56 (71.8) 
Types of hypnotics used – # (%)*   
 Zopiclone 30 (53.6) 
 Trazodone 7 (12.5) 
 Melatonin 6 (10.7) 
 Benzodiazepine 5 (8.9) 
 Quetiapine 5 (8.9) 
 Tricyclic antidepressant 4 (7.1) 
 Dimenhydrinate 2 (3.6) 
 Diphenhydramine 2 (3.6) 
 Other^ 3 (5.4) 
Alcohol (6 hr before bed) - # (%)  11 (14.1) 
Current smoking – # (%)   3 (3.8) 
Caffeine (6 hr before bed) – # (%)  29 (37.1) 
*  Percentages add up to more than 100 because some patients were taking multiple hypnotics   
^  Hydroxyzine, mirtazapine, cannabis 
 
 
 
 
 
 
  
Table 2 – Patient Self-Reported Sleep Diary Parameters 
 
Parameter Baseline Post CBT-i p-value N4 
Sleep onset latency1 - minutes 47.9 28.0 <0.001 64 
Wake after sleep onset2 - 
minutes 
60.7 36.2 <0.001 57 
Number of awakenings 2.0 1.7 0.0033 61 
Total time in bed - minutes 490.1  440.0  <0.001 65 
Total sleep time - minutes 382.0  378.4  0.603 66 
Sleep efficiency3 78.2% 86.1% <0.001 65 
Insomnia severity index (ISI) 
score 
18.2 7.9 <0.001 17 
 
1. Sleep onset latency – the time it takes for an individual to fall asleep 
2. Wake after sleep onset – the total duration of awakenings during the night after initially falling asleep 
3. Sleep efficiency – the proportion of time spent in bed while being asleep 
4. Numbers vary as some sleep parameters were not recorded in charts for all patients  
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Figure 1 – Patient recruitment 
 
 
 
 
 
183 patients referred to pharmacist for CBT-i 
183 patients attend initial CBT-i appointment with 
pharmacist 
105 patients excluded 
19 patients deemed by 
pharmacist to be poor 
candidate for CBT-i 
32 patients declined CBT-i after 
initial appointment 
54 patients did not return for 
follow up appointment for 
unknown reason 
 
78  patients met inclusion criteria  
(>18 years old, received entire CBT-i 
intervention from pharmacist)  
